What Omnicell, Inc. told the SEC could break it.

Omnicell's demand depends on health systems' capital and operating budgets, which are under acute policy-driven pressure. It cites 340B margin compression driven by the Inflation Reduction Act, site-neutral payment cuts, and sweeping health-policy/legislative changes estimated to cut direct reimbursements by roughly $910 billion over the coming years — which, combined with rising tariffs and labor costs, is projected to severely compress hospital operating margins. If customers defer or cut capital spending on automation in response, Omnicell's bookings and revenue could weaken. A specific, demand-side healthcare-policy exposure transmitted through its customers' finances.

“health systems are navigating sweeping changes in health policy and potential legislative actions that are estimated to result in a $910 billion reduction in direct reimbursements over the coming years.”

Omnicell sources components and runs supply-chain operations in Asia and the Americas, so U.S. import tariffs raise its hardware cost base. It discloses that in 2025 the U.S. imposed tariffs on a wide variety of products manufactured in multiple foreign jurisdictions including China, Mexico and Malaysia, that affected countries imposed reciprocal tariffs on U.S.-made goods, and that these rates have fluctuated and may continue to. It also notes the February 20, 2026 U.S. Supreme Court decision striking down certain IEEPA-based tariffs, the impact of which is unclear. The uncertainty and cost volatility around tariffs on its imported components is a concrete trade-policy exposure on top of the demand-side healthcare-policy pressure.

Omnicell sells its medication-management automation primarily through group purchasing organizations (GPOs) and government channels: sales to members of its ten largest GPOs and to federal agencies purchasing under the GSA Contract collectively accounted for approximately 61% of total consolidated revenue in 2025. While receivables sit with individual GPO members (limiting credit concentration), the contracting relationships are concentrated — loss of a GPO agreement, GSA contract, or adverse repricing would impair access to a large share of the customer base. The GPOs are not named in the filing, so this registers as a channel/customer concentration risk.

“During our fiscal year ended December 31, 2025, sales to members of the ten largest GPOs and federal agencies that purchase under the GSA Contract collectively accounted for approximately 61% of our total consolidated revenues.”

Omnicell relies on a few single-source third-party manufacturers to build several of its hardware sub-assemblies, and certain components/subsystems are fabricated by a single supplier to its specifications or available only from limited sources (it has entered supplier relationships specifically for components of its XT Series and Titan XT products). On the consumables side, it depends on a limited number of suppliers for the raw materials used to produce its medication packages, which are made on a continuous basis at a single facility in St. Petersburg, Florida (~8% of revenue). A reduction, interruption, or price spike at a sole-source sub-assembly partner or consumable raw-material supplier — or disruption at the St. Petersburg plant — could halt production or force costly substitutions. Suppliers are unnamed, so this registers as a sole-source/single-site risk.

“We engage multiple single source third-party manufacturers to build several of our sub-assemblies.”